COVID-19 Impact on Global Dilated Cardiomyopathy Therapeutic Market Size, Status and Forecast 2020-2026

August 2020 | 97 pages | ID: C00624DC2DD1EN
QYResearch

Abstracts

This report focuses on the global Dilated Cardiomyopathy Therapeutic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Dilated Cardiomyopathy Therapeutic development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Array BioPharma, Inc.
• AstraZeneca plc.
• Celladon Corporation
• GlaxoSmithKline plc
• Janssen Pharmaceuticals, Inc. (J&J)
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Vericel Corporation

Market segment by Type, the product can be split into

• Aldosterone antagonists
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin II receptor blockers (ARBs)
• Beta-blockers

Market segment by Application, split into

• Hospitals
• Academic Institutions

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Dilated Cardiomyopathy Therapeutic status, future forecast, growth opportunity, key market and key players.
• To present the Dilated Cardiomyopathy Therapeutic development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Dilated Cardiomyopathy Therapeutic are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Dilated Cardiomyopathy Therapeutic Revenue
1.4 Market Analysis by Type
  1.4.1 Global Dilated Cardiomyopathy Therapeutic Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Aldosterone antagonists
  1.4.3 Angiotensin-converting enzyme (ACE) inhibitors
  1.4.4 Angiotensin II receptor blockers (ARBs)
  1.4.5 Beta-blockers
1.5 Market by Application
  1.5.1 Global Dilated Cardiomyopathy Therapeutic Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Academic Institutions
1.6 Coronavirus Disease 2019 (Covid-19): Dilated Cardiomyopathy Therapeutic Industry Impact
  1.6.1 How the Covid-19 is Affecting the Dilated Cardiomyopathy Therapeutic Industry
    1.6.1.1 Dilated Cardiomyopathy Therapeutic Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Dilated Cardiomyopathy Therapeutic Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Dilated Cardiomyopathy Therapeutic Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Dilated Cardiomyopathy Therapeutic Market Perspective (2015-2026)
2.2 Dilated Cardiomyopathy Therapeutic Growth Trends by Regions
  2.2.1 Dilated Cardiomyopathy Therapeutic Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Dilated Cardiomyopathy Therapeutic Historic Market Share by Regions (2015-2020)
  2.2.3 Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Dilated Cardiomyopathy Therapeutic Market Growth Strategy
  2.3.6 Primary Interviews with Key Dilated Cardiomyopathy Therapeutic Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Dilated Cardiomyopathy Therapeutic Players by Market Size
  3.1.1 Global Top Dilated Cardiomyopathy Therapeutic Players by Revenue (2015-2020)
  3.1.2 Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Players (2015-2020)
  3.1.3 Global Dilated Cardiomyopathy Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Dilated Cardiomyopathy Therapeutic Market Concentration Ratio
  3.2.1 Global Dilated Cardiomyopathy Therapeutic Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Dilated Cardiomyopathy Therapeutic Revenue in 2019
3.3 Dilated Cardiomyopathy Therapeutic Key Players Head office and Area Served
3.4 Key Players Dilated Cardiomyopathy Therapeutic Product Solution and Service
3.5 Date of Enter into Dilated Cardiomyopathy Therapeutic Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Dilated Cardiomyopathy Therapeutic Historic Market Size by Type (2015-2020)
4.2 Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Type (2021-2026)

5 DILATED CARDIOMYOPATHY THERAPEUTIC BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)
5.2 Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
6.2 Dilated Cardiomyopathy Therapeutic Key Players in North America (2019-2020)
6.3 North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
6.4 North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
7.2 Dilated Cardiomyopathy Therapeutic Key Players in Europe (2019-2020)
7.3 Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
7.4 Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

8 CHINA

8.1 China Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
8.2 Dilated Cardiomyopathy Therapeutic Key Players in China (2019-2020)
8.3 China Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
8.4 China Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
9.2 Dilated Cardiomyopathy Therapeutic Key Players in Japan (2019-2020)
9.3 Japan Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
9.4 Japan Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
10.2 Dilated Cardiomyopathy Therapeutic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
10.4 Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

11 INDIA

11.1 India Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
11.2 Dilated Cardiomyopathy Therapeutic Key Players in India (2019-2020)
11.3 India Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
11.4 India Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Dilated Cardiomyopathy Therapeutic Market Size (2015-2020)
12.2 Dilated Cardiomyopathy Therapeutic Key Players in Central & South America (2019-2020)
12.3 Central & South America Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020)
12.4 Central & South America Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Array BioPharma, Inc.
  13.1.1 Array BioPharma, Inc. Company Details
  13.1.2 Array BioPharma, Inc. Business Overview and Its Total Revenue
  13.1.3 Array BioPharma, Inc. Dilated Cardiomyopathy Therapeutic Introduction
  13.1.4 Array BioPharma, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020))
  13.1.5 Array BioPharma, Inc. Recent Development
13.2 AstraZeneca plc.
  13.2.1 AstraZeneca plc. Company Details
  13.2.2 AstraZeneca plc. Business Overview and Its Total Revenue
  13.2.3 AstraZeneca plc. Dilated Cardiomyopathy Therapeutic Introduction
  13.2.4 AstraZeneca plc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.2.5 AstraZeneca plc. Recent Development
13.3 Celladon Corporation
  13.3.1 Celladon Corporation Company Details
  13.3.2 Celladon Corporation Business Overview and Its Total Revenue
  13.3.3 Celladon Corporation Dilated Cardiomyopathy Therapeutic Introduction
  13.3.4 Celladon Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.3.5 Celladon Corporation Recent Development
13.4 GlaxoSmithKline plc
  13.4.1 GlaxoSmithKline plc Company Details
  13.4.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
  13.4.3 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Introduction
  13.4.4 GlaxoSmithKline plc Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.4.5 GlaxoSmithKline plc Recent Development
13.5 Janssen Pharmaceuticals, Inc. (J&J)
  13.5.1 Janssen Pharmaceuticals, Inc. (J&J) Company Details
  13.5.2 Janssen Pharmaceuticals, Inc. (J&J) Business Overview and Its Total Revenue
  13.5.3 Janssen Pharmaceuticals, Inc. (J&J) Dilated Cardiomyopathy Therapeutic Introduction
  13.5.4 Janssen Pharmaceuticals, Inc. (J&J) Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.5.5 Janssen Pharmaceuticals, Inc. (J&J) Recent Development
13.6 Merck & Co., Inc.
  13.6.1 Merck & Co., Inc. Company Details
  13.6.2 Merck & Co., Inc. Business Overview and Its Total Revenue
  13.6.3 Merck & Co., Inc. Dilated Cardiomyopathy Therapeutic Introduction
  13.6.4 Merck & Co., Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.6.5 Merck & Co., Inc. Recent Development
13.7 Novartis International AG
  13.7.1 Novartis International AG Company Details
  13.7.2 Novartis International AG Business Overview and Its Total Revenue
  13.7.3 Novartis International AG Dilated Cardiomyopathy Therapeutic Introduction
  13.7.4 Novartis International AG Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.7.5 Novartis International AG Recent Development
13.8 Pfizer, Inc.
  13.8.1 Pfizer, Inc. Company Details
  13.8.2 Pfizer, Inc. Business Overview and Its Total Revenue
  13.8.3 Pfizer, Inc. Dilated Cardiomyopathy Therapeutic Introduction
  13.8.4 Pfizer, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.8.5 Pfizer, Inc. Recent Development
13.9 Sanofi S.A.
  13.9.1 Sanofi S.A. Company Details
  13.9.2 Sanofi S.A. Business Overview and Its Total Revenue
  13.9.3 Sanofi S.A. Dilated Cardiomyopathy Therapeutic Introduction
  13.9.4 Sanofi S.A. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.9.5 Sanofi S.A. Recent Development
13.10 Teva Pharmaceutical Industries Ltd.
  13.10.1 Teva Pharmaceutical Industries Ltd. Company Details
  13.10.2 Teva Pharmaceutical Industries Ltd. Business Overview and Its Total Revenue
  13.10.3 Teva Pharmaceutical Industries Ltd. Dilated Cardiomyopathy Therapeutic Introduction
  13.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  13.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
13.11 Vericel Corporation
  10.11.1 Vericel Corporation Company Details
  10.11.2 Vericel Corporation Business Overview and Its Total Revenue
  10.11.3 Vericel Corporation Dilated Cardiomyopathy Therapeutic Introduction
  10.11.4 Vericel Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
  10.11.5 Vericel Corporation Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Dilated Cardiomyopathy Therapeutic Key Market Segments
Table 2. Key Players Covered: Ranking by Dilated Cardiomyopathy Therapeutic Revenue
Table 3. Ranking of Global Top Dilated Cardiomyopathy Therapeutic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Dilated Cardiomyopathy Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Aldosterone antagonists
Table 6. Key Players of Angiotensin-converting enzyme (ACE) inhibitors
Table 7. Key Players of Angiotensin II receptor blockers (ARBs)
Table 8. Key Players of Beta-blockers
Table 9. COVID-19 Impact Global Market: (Four Dilated Cardiomyopathy Therapeutic Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Dilated Cardiomyopathy Therapeutic Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Dilated Cardiomyopathy Therapeutic Players to Combat Covid-19 Impact
Table 14. Global Dilated Cardiomyopathy Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Dilated Cardiomyopathy Therapeutic Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Dilated Cardiomyopathy Therapeutic Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions (2015-2020)
Table 18. Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Dilated Cardiomyopathy Therapeutic Market Growth Strategy
Table 24. Main Points Interviewed from Key Dilated Cardiomyopathy Therapeutic Players
Table 25. Global Dilated Cardiomyopathy Therapeutic Revenue by Players (2015-2020) (Million US$)
Table 26. Global Dilated Cardiomyopathy Therapeutic Market Share by Players (2015-2020)
Table 27. Global Top Dilated Cardiomyopathy Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dilated Cardiomyopathy Therapeutic as of 2019)
Table 28. Global Dilated Cardiomyopathy Therapeutic by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Dilated Cardiomyopathy Therapeutic Product Solution and Service
Table 31. Date of Enter into Dilated Cardiomyopathy Therapeutic Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 34. Global Dilated Cardiomyopathy Therapeutic Market Size Share by Type (2015-2020)
Table 35. Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Type (2021-2026)
Table 36. Global Dilated Cardiomyopathy Therapeutic Market Size Share by Application (2015-2020)
Table 37. Global Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 38. Global Dilated Cardiomyopathy Therapeutic Market Size Share by Application (2021-2026)
Table 39. North America Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 41. North America Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 42. North America Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 43. North America Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 44. North America Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 45. Europe Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 47. Europe Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 49. Europe Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 51. China Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 52. China Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 53. China Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 54. China Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 55. China Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 56. China Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 57. Japan Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 59. Japan Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 61. Japan Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 65. Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 67. Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 69. India Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 70. India Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 71. India Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 72. India Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 73. India Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 74. India Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Dilated Cardiomyopathy Therapeutic Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Dilated Cardiomyopathy Therapeutic Market Share (2019-2020)
Table 77. Central & South America Dilated Cardiomyopathy Therapeutic Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Dilated Cardiomyopathy Therapeutic Market Share by Type (2015-2020)
Table 79. Central & South America Dilated Cardiomyopathy Therapeutic Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Dilated Cardiomyopathy Therapeutic Market Share by Application (2015-2020)
Table 81. Array BioPharma, Inc. Company Details
Table 82. Array BioPharma, Inc. Business Overview
Table 83. Array BioPharma, Inc. Product
Table 84. Array BioPharma, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 85. Array BioPharma, Inc. Recent Development
Table 86. AstraZeneca plc. Company Details
Table 87. AstraZeneca plc. Business Overview
Table 88. AstraZeneca plc. Product
Table 89. AstraZeneca plc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 90. AstraZeneca plc. Recent Development
Table 91. Celladon Corporation Company Details
Table 92. Celladon Corporation Business Overview
Table 93. Celladon Corporation Product
Table 94. Celladon Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 95. Celladon Corporation Recent Development
Table 96. GlaxoSmithKline plc Company Details
Table 97. GlaxoSmithKline plc Business Overview
Table 98. GlaxoSmithKline plc Product
Table 99. GlaxoSmithKline plc Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 100. GlaxoSmithKline plc Recent Development
Table 101. Janssen Pharmaceuticals, Inc. (J&J) Company Details
Table 102. Janssen Pharmaceuticals, Inc. (J&J) Business Overview
Table 103. Janssen Pharmaceuticals, Inc. (J&J) Product
Table 104. Janssen Pharmaceuticals, Inc. (J&J) Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 105. Janssen Pharmaceuticals, Inc. (J&J) Recent Development
Table 106. Merck & Co., Inc. Company Details
Table 107. Merck & Co., Inc. Business Overview
Table 108. Merck & Co., Inc. Product
Table 109. Merck & Co., Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 110. Merck & Co., Inc. Recent Development
Table 111. Novartis International AG Company Details
Table 112. Novartis International AG Business Overview
Table 113. Novartis International AG Product
Table 114. Novartis International AG Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 115. Novartis International AG Recent Development
Table 116. Pfizer, Inc. Business Overview
Table 117. Pfizer, Inc. Product
Table 118. Pfizer, Inc. Company Details
Table 119. Pfizer, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 120. Pfizer, Inc. Recent Development
Table 121. Sanofi S.A. Company Details
Table 122. Sanofi S.A. Business Overview
Table 123. Sanofi S.A. Product
Table 124. Sanofi S.A. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 125. Sanofi S.A. Recent Development
Table 126. Teva Pharmaceutical Industries Ltd. Company Details
Table 127. Teva Pharmaceutical Industries Ltd. Business Overview
Table 128. Teva Pharmaceutical Industries Ltd. Product
Table 129. Teva Pharmaceutical Industries Ltd. Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 130. Teva Pharmaceutical Industries Ltd. Recent Development
Table 131. Vericel Corporation Company Details
Table 132. Vericel Corporation Business Overview
Table 133. Vericel Corporation Product
Table 134. Vericel Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2015-2020) (Million US$)
Table 135. Vericel Corporation Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Dilated Cardiomyopathy Therapeutic Market Share by Type: 2020 VS 2026
Figure 2. Aldosterone antagonists Features
Figure 3. Angiotensin-converting enzyme (ACE) inhibitors Features
Figure 4. Angiotensin II receptor blockers (ARBs) Features
Figure 5. Beta-blockers Features
Figure 6. Global Dilated Cardiomyopathy Therapeutic Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Academic Institutions Case Studies
Figure 9. Dilated Cardiomyopathy Therapeutic Report Years Considered
Figure 10. Global Dilated Cardiomyopathy Therapeutic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions: 2020 VS 2026
Figure 12. Global Dilated Cardiomyopathy Therapeutic Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Dilated Cardiomyopathy Therapeutic Market Share by Players in 2019
Figure 15. Global Top Dilated Cardiomyopathy Therapeutic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Dilated Cardiomyopathy Therapeutic as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Dilated Cardiomyopathy Therapeutic Revenue in 2019
Figure 17. North America Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Dilated Cardiomyopathy Therapeutic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Array BioPharma, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Array BioPharma, Inc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 26. AstraZeneca plc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. AstraZeneca plc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 28. Celladon Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Celladon Corporation Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 30. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. GlaxoSmithKline plc Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 32. Janssen Pharmaceuticals, Inc. (J&J) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Janssen Pharmaceuticals, Inc. (J&J) Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 34. Merck & Co., Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Merck & Co., Inc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 36. Novartis International AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Novartis International AG Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 38. Pfizer, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Pfizer, Inc. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 40. Sanofi S.A. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Sanofi S.A. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 42. Teva Pharmaceutical Industries Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 44. Vericel Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Vericel Corporation Revenue Growth Rate in Dilated Cardiomyopathy Therapeutic Business (2015-2020)
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed